FilingReader Intelligence
J.B. Chemicals gains US FDA approval for Bisoprolol
April 18, 2025 at 07:01 PM UTC•By FilingReader AI
J.B. Chemicals & Pharmaceuticals (BSE:JBCHEPHARM) announced today that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Bisoprolol Tablets USP, in 5 mg and 10 mg dosages. The drug is a generic version of Zebeta (Teva) and is indicated for the management of hypertension. The company has requested that the announcement be taken on record.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:JBCHEPHARM•Bombay Stock Exchange
News Alerts
Get instant email alerts when J.B. Chemicals & Pharmaceuticals publishes news
Free account required • Unsubscribe anytime